PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

PLIANT THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$0.90−0.00 (-0.13%)

Close on Oct 19, 2026

Market cap: $55.65M
P/E (TTM): –
Dividend yield: 0.00%

PLIANT THERAPEUTICS, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Stock-Based Compensation	26	38	44	23	10	3.90	1.83
Change in Accounts Receivable	–	0	1.98	0.02	7.28	-2.23	-7.05
Change in Accounts Payable	-5.48	1.43	2.97	-1.35	0.89	0.92	-1.26
Operating Cash Flow	-128	-156	-116	-95	-75	-37	-2.75
Capital Expenditures	-0.37	-3.85	-0.92	-1.76	-1.95	-1.53	-0.96
Sale of Property, Plant & Equipment	0.16	0	–	–	–	–	–
Purchase of Investments	-203	-211	-583	-326	-220	-323	-52
Investing Cash Flow	134	140	-127	-150	74	-211	-18
Debt Issued	0	20	0	9.85	0	–	–
Debt Repaid	-32	0	–	–	–	–	–
Financing Cash Flow	-32	23	274	227	2.53	213	46
Net Change in Cash	-26	7.95	31	-18	0.78	-35	25
Free Cash Flow	-129	-159	-117	-96	-77	-39	-3.71
Income Taxes Paid	0	0	–	–	–	–	–
Interest Paid	2.54	2.62	1.15	0.62	0	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -61.5%

Financial strength

Current ratio: 9.90
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 151.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.38
Dividend yield: 0.00%